KALAMAZOO, Mich.--(BUSINESS WIRE)--ADMETRx, a Michigan-based privately held Contract Research Organization (CRO) that provides customized solutions to the pharmaceutical and biotechnology industries in making preclinical drug candidate advancement decisions, announced that company co-founder, Philip S. Burton, PhD, has accepted an appointment to the advisory board of Locus Pharmaceuticals. With 25 years of experience in medicinal and biopharmaceutical chemistry and drug absorption, Dr. Burton, also the CEO and CSO of ADMETRx, is an internationally recognized thought-leader in modeling drug absorption and a frequent invited lecturer to numerous national and international symposia.
